Law Offices of Howard G. Smith continues its investigation on behalf of Cryoport, Inc. (“Cryoport” or the “Company”) (NASDAQ: CYRX) investors concerning the Company’s possible violations of federal securities laws.

On July 12, 2023, after market hours, Cryoport announced preliminary second-quarter financial results, and disclosed that its second quarter 2023 total revenue “is expected to be in the range of $56.5 to $57.5 million, representing a decrease of 11%, at the midpoint, compared to the second quarter of 2022.” The Company attributed the shortfall to “a global slowdown in capital equipment investment” as well as “a number of clinical trial start delays and several key customers falling short of their forecasts for the revenue ramp of certain cell and gene therapies.”

On this news, Cryoport’s stock price fell as $4.80, or 24.7%, to close at $14.60 per share on July 13, 2023, thereby injuring investors.

If you purchased Cryoport securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230911735892/en/